Drug Development

Blog Post

MDA’s 2020 Advocacy Plan

By Mark Fisher | January 27, 2020
Blog Post

Clinical Trial Alert: Individuals with SMA Type 3 Sought for a Phase 2 Study

By MDA Staff | January 27, 2020
Blog Post

Antisense Therapeutics Announces Positive Results from Phase 2 Study of ATL1102 in DMD

By Jeanene Swanson | January 24, 2020
Blog Post

Amylyx Pharmaceuticals Announces Positive Results from Phase 2 Study of AMX0035 for Treatment of ALS

By Jeanene Swanson | December 19, 2019
Blog Post

Santhera Pharmaceuticals Announces Publication of Positive Long-Term Results from Retrospective Study of Idebenone in DMD

By Jeanene Swanson | December 18, 2019
MDA logo
Blog Post

Solid Biosciences Releases Letter to DMD Community Announcing Update on IGNITE DMD Trial, Resolution of Serious Adverse Event

By MDA Staff | December 18, 2019
MDA logo
Blog Post

Wave Life Sciences Releases Letter to DMD Community Announcing Discontinuation of Clinical Trials Program for Therapies Amenable to Skipping Exons 51 and 53

By MDA Staff | December 16, 2019
Blog Post

Kadimastem Announces Positive Interim Results from Phase 1/2a Study of AstroRx in ALS

By Jeanene Swanson | December 5, 2019
Illustration of DNA
Blog Post

FDA Accepts Roche Genentech’s NDA for Risdiplam for the Treatment of SMA

By Jeanene Swanson | December 3, 2019
Blog Post

Roche Genentech Announces Positive Results from Pivotal Study of Risdiplam in SMA Types 2 and 3

By Jeanene Swanson | November 15, 2019